Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc., a leading biopharmaceutical company based in the United States, focuses on developing innovative treatments for neuropsychiatric diseases. Founded in 2002, the company has made significant strides in the industry, particularly with its flagship product, Caplyta (lumateperone), which has garnered attention for its unique mechanism of action in treating schizophrenia and bipolar depression.
With a strong presence in the US and expanding operations in key global markets, Intra-Cellular Therapies is committed to addressing unmet medical needs through its cutting-edge research and development efforts. The company’s dedication to advancing mental health therapies positions it as a notable player in the biopharmaceutical landscape, with a focus on improving patient outcomes and enhancing quality of life.
+33 vs industry average
Intra-Cellular Therapies, Inc.’s score of 71 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Intra-Cellular Therapies, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Intra-Cellular Therapies, Inc. yet.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Intra-Cellular Therapies, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Intra-Cellular Therapies, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from Johnson & Johnson
Carbon Disclosure Project
Inherited from Johnson & Johnson
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Inherited from Johnson & Johnson
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Intra-Cellular Therapies, Inc.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project